Exogenous Recombinant Adiponectin Improves Survival in Experimental Abdominal Sepsis

Volume: 31 Number: 3 July 1, 2014
  • Bülent Salman
  • Tonguç Utku Yılmaz
  • Tugan Tezcaner
  • Ebru Ofluoğlu Demir
  • Özge Tuğçe Paşaoğlu
EN

Exogenous Recombinant Adiponectin Improves Survival in Experimental Abdominal Sepsis

Abstract

_Adiponectin, which has anti-inflammatory features, is an important substance in several metabolic mechanisms. Aims_ The aim of this study is to evauate the effects of exogenous intraperitoneal administration of adiponectin on the survival, intrabdominal adhesion and inflammatory cytokine levels in an experimental sepsis model. Study Design_ Animal experimentation. Methods_ Ninety rats were divided into a control group, adiponectin group and sham group. A cecal puncture abdominal sepsis model was performed in the adiponectin and control groups. Every three hours, exogenous adiponectin was administrated to the adiponectin group. At the 3rd and 24th hours, 10 rats were sacrified in each group in order to measure plasma tumor necrosis factor-α (TNF-α), interleukin (IL) 10, soluble intracellular adhesion molecule (ICAM)-1, IL-6 and macrophage inhibitory factor levels, and the activity of nuclear factor (NF)-kB. The remaining rats were followed for survival. Results_ The plasma levels of TNF-α, soluable ICAM-1, IL-6, and macrophage inhibitory factor were significantly higher in the control group than in the adiponectin and sham group (p_0.05). The increase in inflammatory cytokines with time was more prominent in the control group. The activity of NF-kB in the control group was higher than in the adiponectin group (p_0.05). The survival rate of the adiponectin group was higher than in the control group. Conclusion_ Administration of exogenous adiponectin to the peritoneum in abdominal sepsis increased survival and decreased intrabdominal adhesions by decreasing the inflammatory response_

Keywords

References

  1. 1. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005;365:63-78. [CrossRef]
  2. 2. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, et al. Cytokine profiles as markers of disease severity in sepsis: A multiple analysis. Crit Care 2007;11:R49. [CrossRef]
  3. 3. Baugh JA, Bucala R. Macrophage migration inhibitory factor. Crit Care Med 2002;30:27-35. [CrossRef]
  4. 4. Bedirli A, Salman B, Pasaoglu H, Ofluoglu E, Sakrak O. Effects of nuclear faktor-kB ınhıbıtors on colon anastomıc healing rats. J Surg Res 2011;171:355-60. [CrossRef]
  5. 5. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007;380:24-30. [CrossRef]
  6. 6. Tsuchihashi H, Yamamoto H, Maeda K, Ugi S, Shimizu T, Endo Y, et al. Circulating concentrations of adiponectin, an endogenous lipopolysaccharide neutralizing protein, decrease in rats with polymicrobial sepsis. J Sur Res 2006;134:348-53. [CrossRef]
  7. 7. Uji Y, Yamamoto H, Tsuchihashi H, Maeda K, Funahashi T, Shimomura I, et al. Adiponectin deficiency is associated with severe polymicrobial sepsis, high inflammatory cytokine levels, and high mortality. Surgery 2009;145:550-7. [CrossRef]
  8. 8. Uji Y, Yamamoto H, Maeda K, Tsuchihashi H, Akabori H, Shimizu T, et al. Adiponectin deficiency promotes the production of inflammatory mediators while severely exacerbating hepatic injury in mice with polymicrobial sepsis. J Surg Res 2010;161:301-11. [CrossRef]

Details

Primary Language

English

Subjects

-

Journal Section

-

Authors

Bülent Salman This is me

Tonguç Utku Yılmaz This is me

Tugan Tezcaner This is me

Ebru Ofluoğlu Demir This is me

Özge Tuğçe Paşaoğlu This is me

Publication Date

July 1, 2014

Submission Date

July 1, 2014

Acceptance Date

-

Published in Issue

Year 2014 Volume: 31 Number: 3

APA
Salman, B., Yılmaz, T. U., Tezcaner, T., Demir, E. O., & Paşaoğlu, Ö. T. (2014). Exogenous Recombinant Adiponectin Improves Survival in Experimental Abdominal Sepsis. Balkan Medical Journal, 31(3), 244-248. https://izlik.org/JA58WN79DL
AMA
1.Salman B, Yılmaz TU, Tezcaner T, Demir E O, Paşaoğlu ÖT. Exogenous Recombinant Adiponectin Improves Survival in Experimental Abdominal Sepsis. Balkan Medical Journal. 2014;31(3):244-248. https://izlik.org/JA58WN79DL
Chicago
Salman, Bülent, Tonguç Utku Yılmaz, Tugan Tezcaner, Ebru Ofluoğlu Demir, and Özge Tuğçe Paşaoğlu. 2014. “Exogenous Recombinant Adiponectin Improves Survival in Experimental Abdominal Sepsis”. Balkan Medical Journal 31 (3): 244-48. https://izlik.org/JA58WN79DL.
EndNote
Salman B, Yılmaz TU, Tezcaner T, Demir E O, Paşaoğlu ÖT (July 1, 2014) Exogenous Recombinant Adiponectin Improves Survival in Experimental Abdominal Sepsis. Balkan Medical Journal 31 3 244–248.
IEEE
[1]B. Salman, T. U. Yılmaz, T. Tezcaner, E. O. Demir, and Ö. T. Paşaoğlu, “Exogenous Recombinant Adiponectin Improves Survival in Experimental Abdominal Sepsis”, Balkan Medical Journal, vol. 31, no. 3, pp. 244–248, July 2014, [Online]. Available: https://izlik.org/JA58WN79DL
ISNAD
Salman, Bülent - Yılmaz, Tonguç Utku - Tezcaner, Tugan - Demir, Ebru Ofluoğlu - Paşaoğlu, Özge Tuğçe. “Exogenous Recombinant Adiponectin Improves Survival in Experimental Abdominal Sepsis”. Balkan Medical Journal 31/3 (July 1, 2014): 244-248. https://izlik.org/JA58WN79DL.
JAMA
1.Salman B, Yılmaz TU, Tezcaner T, Demir E O, Paşaoğlu ÖT. Exogenous Recombinant Adiponectin Improves Survival in Experimental Abdominal Sepsis. Balkan Medical Journal. 2014;31:244–248.
MLA
Salman, Bülent, et al. “Exogenous Recombinant Adiponectin Improves Survival in Experimental Abdominal Sepsis”. Balkan Medical Journal, vol. 31, no. 3, July 2014, pp. 244-8, https://izlik.org/JA58WN79DL.
Vancouver
1.Bülent Salman, Tonguç Utku Yılmaz, Tugan Tezcaner, Ebru Ofluoğlu Demir, Özge Tuğçe Paşaoğlu. Exogenous Recombinant Adiponectin Improves Survival in Experimental Abdominal Sepsis. Balkan Medical Journal [Internet]. 2014 Jul. 1;31(3):244-8. Available from: https://izlik.org/JA58WN79DL